AYTU BioPharma (AYTU)

• Market cap: $9.41M
• 1 day: 2.00%
• 5 days: 9.29%
• 1 month: -4.38%
• 3 months: -46.32%
• 6 months: -46.88%
• Year to date: -47.06%
• 1 year: -49.17%
• 5 years: -99.25%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Employees: 102

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% less funds holding

Funds holding: 27 [Q2] → 24 (-3) [Q3]

19.31% less ownership

Funds ownership: 52.61% [Q2] → 33.31% (-19.31%) [Q3]

48% less capital invested

Capital invested by funds: $9.17M [Q2] → $4.81M (-$4.36M) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4